HENLIUS (02696)The clinical trial application for the treatment of advanced squamous non-small cell lung cancer with PIMURUTAMAB HLX07 in combination with Hanxiuzhuang and chemotherapy has been approved by the National Medical Products Administration.
Fuhong Hanlin (02696) announced that recently, the company's independently developed pimurutamab
HLX07 (recombinant anti-EGFR humanized monoclonal antibody injection) (HLX07) in combination with Hanslu (sorafenib injection) (Hanslu) and chemotherapy for the treatment of advanced squamous non-small cell lung cancer (sqNSCLC) has received approval from the National Medical Products Administration (NMPA) for clinical trial application.
HENLIUS (02696) announced that recently, the company's self-developed pimurutamab HLX07 (recombinant anti-EGFR humanized monoclonal antibody injection) (HLX07) in combination with Hanchar (Sulituzumab injection) (Hanchar) and chemotherapy for the treatment of advanced squamous non-small cell lung cancer (sqNSCLC) has been approved for clinical trial by the National Medical Products Administration (NMPA).
Related Articles
Ahsay Backup (08290) announces a pleasing profit growth, with an anticipated annual net profit not exceeding 1 million Hong Kong dollars in 2025, turning from a loss to a profit year-on-year.
Dalian Zhiyun Automation (300097.SZ) plans to raise funds of up to 250 million yuan through a private placement to its controlling shareholder Huida Fuheng.
STERLING GP (01825) reduced 373 million shares due to a 10-for-1 consolidation.
Ahsay Backup (08290) announces a pleasing profit growth, with an anticipated annual net profit not exceeding 1 million Hong Kong dollars in 2025, turning from a loss to a profit year-on-year.
Dalian Zhiyun Automation (300097.SZ) plans to raise funds of up to 250 million yuan through a private placement to its controlling shareholder Huida Fuheng.
STERLING GP (01825) reduced 373 million shares due to a 10-for-1 consolidation.
